Antioxidant, anti-inflammatory, and wound healing effects of topical silver-doped zinc oxide and silver oxide nanocomposites.

Silver nanoparticles (Ag-NPs), silver oxide nanoparticles (AgO-NPs), and zinc oxide nanoparticles (ZnO-NPs) have healing, antibacterial, and antioxidant properties. Furthermore, Ag-NPs and ZnO-NPs also have anti-inflammatory properties. In this study, we synthesized a nanocomposite using Ag-ZnO and AgO-NPs (Ag-ZnO/AgO NPs). The structural and morphological properties of nanocrystals and nanocomposite were investigated by X-ray diffraction and scanning electronics microscopic. The wurtzite crystalline structure of Ag-ZnO and two morphologies for the nanocomposite (nanorods and nanoplatelets) were determined. Topical treatment with 1% Ag-ZnO/AgO NPs was compared to untreated wounds (control group). Wounds were induced in the dorsal region of BALB/c mice and evaluated after 3, 7, 14, and 21 days of treatment. The nanocomposite demonstrated anti-inflammatory and antioxidant capacities. In addition, wounds treated with Ag-ZnO/AgO NPs showed accelerated closure, non-cytotoxicity, especially on keratinocytes and collagen deposition, and increased metalloproteinases 2 and 9 activity. The nanocomposite improved healing by reducing the inflammatory process, protecting tissues from damage caused by free radicals, and increasing collagen deposition in the extracellular matrix. These characteristics contributed to the accelerated wound closure process. Thus, Ag-ZnO/AgO NPs show potential for can be a strategy for topical use in formulations of new drugs to treat wounds.

Increased Dietary Leucine Reduces Doxorubicin-Associated Cardiac Dysfunction in Rats.

Cardiotoxicity is one of the most significant adverse effects of the oncologic treatment with doxorubicin, which is responsible for a substantial morbid and mortality. The occurrence of heart failure with ventricular dysfunction may lead to severe cardiomyopathy and ultimately to death. Studies have focused on the effects of leucine supplementation as a strategy to minimize or revert the clinical condition of induced proteolysis by several clinical onsets. However, the impact of leucine supplementation in heart failure induced by doxorubicin is unknown. Therefore, the objective of this work is to evaluate the effects of leucine supplementation on the cardiotoxicity in the heart of rats treated with doxorubicin. Rats treated with a 7.5 mg/kg cumulative dose of doxorubicin for 14 days presented a dilatation of the left ventricle (LV), and a reduction of the ejection fraction (FE). The 5% supplementation of leucine in the rats' food prevented the malfunctioning of the LV when administered with doxorubicin. Some alterations in the extracellular matrix remodeling were confirmed by the increase of collagen fibers in the doxorubicin group, which did not increase when the treatment was associated with leucine supplementation. Leucine attenuates heart failure in this experimental model with doxorubicin. Such protection is followed by the maintenance of interstitial collagen fibers.